- In April 2024, ViiV Healthcare, a global leader in HIV treatment, announced the expansion of its Cabenuva (cabotegravir + rilpivirine) long-acting injectable therapy into additional markets, following regulatory approvals in Latin America and Southeast Asia. This move marks a significant step toward increasing global access to long-acting HIV treatment solutions and reflects ViiV’s commitment to patient-centric care and innovation in antiretroviral therapy delivery
- In March 2024, Gilead Sciences, Inc. initiated a Phase III clinical trial to evaluate a novel bictegravir-based dual therapy regimen aimed at reducing long-term side effects while maintaining high viral suppression. This trial underscores Gilead’s strategic focus on treatment simplification and innovation, targeting improved outcomes for treatment-experienced patients and those with comorbidities
- In March 2024, the World Health Organization (WHO) included dolutegravir in updated HIV treatment guidelines for broader use in pediatric populations, following positive safety and efficacy data. This endorsement significantly boosts global confidence in dolutegravir’s utility and supports its expanded use in public health programs, especially in low- and middle-income countries
- In February 2024, Mylan Pharmaceuticals, a subsidiary of Viatris, launched a generic fixed-dose combination of dolutegravir, lamivudine, and tenofovir disoproxil fumarate in sub-Saharan Africa. This launch aims to improve affordability and accessibility in high-burden regions, contributing to global HIV management goals by making quality therapies more widely available
- In January 2024, Janssen Pharmaceuticals announced early development of a next-generation integrase inhibitor targeting HIV strains with resistance to existing drugs. The research is part of Janssen’s broader pipeline expansion strategy focused on novel mechanisms of action and long-acting formulations, reflecting the industry’s ongoing efforts to address drug resistance and improve treatment adherence
